How common is it for patients to present with overlapping cardiac, renal and metabolic issues? A new analysis in JAMA Cardiology explored that very question.

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

Access to cannabis is skyrocketing across the United States, but much more research is still needed on its long-term side effects. 

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

A new study published in JAMA suggests catheter ablation can help AFib patients experience fewer feelings of depression and anxiety.

The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.

The complaint describes Medtronic's actions as “immoral, unethical, oppressive and unscrupulous.”